Explore this week’s obesity highlights, including new developments, pipeline updates, and progress from biopharma leaders.
In this Newsletter
Dive deeper
💊 Lilly triple-agonist retatrutide hits Phase 3 in obesity with knee OA [1] [11 Dec 2025]
Context: TRIUMPH-4, adults with obesity or overweight and knee OA, 68 weeks, 9 mg and 12 mg, no diabetes.
Key point: Met all primary and key secondary endpoints on both estimands, with up to 28.7% mean weight loss and significant WOMAC pain reduction; AE profile consistent with incretins.
Implication: May influence prescriber choice and payer reviews pending full data.
🧪 Ascletis oral GLP-1 ASC30 meets Phase II 13-week endpoint [2] [08 Dec 2025]
Context: U.S. Phase II, n=125, 20–60 mg QD, 13 weeks.
Key point: Placebo-adjusted mean weight loss up to 7.7% at 60 mg; GI AEs mild to moderate, no drug-related SAEs reported.
Implication: May influence prescriber choice and payer reviews pending full data.
📈 Structure Therapeutics aleniglipron delivers 11.3% at 36 weeks [3] [09 Dec 2025]
https://www.clinicaltrialsarena.com/news/structure-therapeutics-aleniglipron-trial/
Context: Phase IIb ACCESS, n=230 adults with obesity or overweight plus comorbidity.
Key point: 120 mg dose showed 11.3% placebo-adjusted mean weight loss at 36 weeks; discontinuations 10.4% across active arms.
Implication: May influence prescriber choice and payer reviews pending full data.
🧬 Innovent mazdutide shows benefit in adolescents (Phase 1b) [4] [11 Dec 2025]
Context: China, Phase 1b, n=36, adolescents 12–<18, 12 weeks, 4 mg and 6 mg vs placebo.
Key point: Statistically significant BMI and weight reductions vs placebo; GI AEs mostly mild to moderate; no SAEs.
Implication: May influence prescriber choice and payer reviews pending full data.
🔺 Boehringer’s triple-agonist BI 3034701 advances mid-stage [5] [12 Dec 2025]
Context: Completed randomized, placebo-controlled Phase I in healthy and overweight/obesity participants.
Key point: Favorable safety and tolerability with encouraging weight-loss signals supports moving to mid-stage.
Implication: Signals pipeline investment and modality expansion.
🩹 LIR Life Sciences files patent for needle-free GLP/GIP delivery [6] [12 Dec 2025]
Context: Provisional USPTO filing for transdermal and lingual delivery platform.
Key point: Aims to enable patches, creams, gels for GLP-/GIP-based medicines, supporting a platform approach.
Implication: Signals pipeline investment and modality expansion.
🧵 Nitinotes treats first patient in pivotal ESG automation trial [7] [10 Dec 2025]
Context: EASE pivotal IDE trial, randomized, two-arm, blinded, EndoZip automated ESG vs manual Apollo OverStitch ESG, up to n=184, US and EU.
Key point: First U.S. patient treated; CE Mark already obtained for EndoZip.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.
🧭 Zealand Pharma unveils Metabolic Frontier 2030 strategy [8] [11 Dec 2025]
Context: Capital Markets Day, London.
Key point: Targets five launches and >10 clinical programs by 2030, expanding peptide and small-molecule capabilities.
Implication: Signals pipeline investment and modality expansion.
🤝 Pfizer licenses YP05002 oral GLP-1 from YaoPharma [9] [09 Dec 2025]
Context: Exclusive global collaboration and license for Phase 1 oral GLP-1.
Key point: $150M upfront, up to $1.935B in milestones plus tiered royalties; Pfizer plans combos with internal small molecules.
Implication: Signals pipeline investment and modality expansion.
💸 Prolynx raises $70M to progress ultra-long-acting incretins [10] [15 Dec 2025]
Context: Series A co-led by 5AM Ventures and OrbiMed; new CEO appointed.
Key point: Funds extended-duration incretin and non-incretin programs toward IND enablement and PoC.
Implication: Signals pipeline investment and modality expansion.
✅ CHMP backs Wegovy 7.2 mg for greater weight loss [11] [12 Dec 2025]
Context: EMA CHMP positive opinion for higher Wegovy dose, with STEP UP data.
Key point: Average weight loss of 20.7% at 72 weeks in non-diabetes obesity; review ongoing in multiple countries.
Implication: Introduces competition that may affect pricing and formulary access.
🩺 Spherix: Physicians expect rapid uptake of oral sema in obesity [12] [09 Dec 2025]
Context: Pipeline pulse among U.S. PCPs and endocrinologists.
Key point: High intent to prescribe within 6 months of approval despite low top-of-mind awareness pre-approval.
Implication: Could streamline initiation and adherence via remote prescribing and logistics.
🧑💼 Crux to offer Zepbound via employer benefit platform [13] [11 Dec 2025]
Context: No-fee platform partnering directly with pharma and employers.
Key point: Zepbound will be first medication; employers contribute pre-tax dollars, launch targeted for early 2026.
Implication: May expand screening, initiation, and follow-up at scale.
Why it matters
- Triple and dual agonists continue to post strong efficacy signals, widening therapeutic options.
- Oral GLP-1s advance on efficacy and convenience, increasing competitive pressure.
- Regulatory momentum for higher-dose semaglutide could reset efficacy benchmarks.
- Capital and BD activity underscore multi-modality investment, including ultra-long-acting and needle-free delivery.
- Access models and procedural innovations aim to bridge demand and real-world delivery.
🚀 Accelerate your success. Contact us now
📂 Explore our case studies. See examples of our work.
💡 Read our insights. Learn from our latest reports and analysis
🎬 Watch on YouTube. Subscribe and never miss a video.
🧰 See our full range of services. Discover how we can help you.
📚 View the full Obesity archive on our research hub page
FAQ
What did Lilly’s TRIUMPH-4 show for retatrutide?
Topline: both 9 mg and 12 mg met primary and key secondary endpoints at 68 weeks with large mean weight loss and WOMAC pain improvements in adults with obesity and knee OA, with GI AEs typical of incretins [1].
How strong are the oral GLP-1 readouts from Ascletis and Structure?
ASC30 achieved up to 7.7% placebo-adjusted mean weight loss at 13 weeks with mild-to-moderate GI AEs in Phase II [2]. Aleniglipron delivered 11.3% placebo-adjusted at 36 weeks in Phase IIb, with 10.4% AE-related discontinuations across active arms [3].
What is the status of higher-dose Wegovy in Europe?
EMA’s CHMP issued a positive opinion for Wegovy 7.2 mg, supported by data showing ~20.7% mean weight loss at 72 weeks in adults without diabetes; final EC decision pending [11].
What did Innovent report in adolescents with obesity?
In a Phase 1b study in China, mazdutide showed statistically significant BMI and weight reductions versus placebo over 12 weeks, with mostly mild to moderate GI AEs and no SAEs reported [4].
What is Pfizer licensing from YaoPharma, and why?
Pfizer secured global rights to YP05002, an oral GLP-1 in Phase 1, paying $150M upfront and up to $1.935B in milestones, and plans combination studies with internal small molecules [9].
Is there progress in non-pharma obesity interventions?
Yes. Nitinotes initiated a pivotal trial comparing automated ESG versus manual suturing, following a CE Mark, aiming to standardize and scale ESG delivery [7].
Entities / Keywords
Retatrutide, Eli Lilly; ASC30, Ascletis; Aleniglipron, Structure Therapeutics; Mazdutide, Innovent; BI 3034701, Boehringer Ingelheim; LIR Life Sciences, needle-free GLP/GIP; EndoZip, Nitinotes, ESG; Zealand Pharma, Metabolic Frontier 2030; Pfizer, YaoPharma, YP05002; Prolynx, ultra-long-acting incretins; Novo Nordisk, Wegovy 7.2 mg, CHMP; Spherix Global Insights; Crux, Zepbound, employer benefits.
References
- https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average
- https://www.prnewswire.com/news-releases/ascletis-oral-small-molecule-glp-1–asc30–demonstrated-placebo-adjusted-weight-loss-of-7-7-with-better-gastrointestinal-tolerability-in-its-13-week-us-phase-ii-study-in-participants-with-obesity-or-overweight-302635182.html
- https://www.clinicaltrialsarena.com/news/structure-therapeutics-aleniglipron-trial/
- https://www.prnewswire.com/news-releases/mazdutide-demonstrates-significant-weight-loss-and-metabolic-benefits-in-phase-1b-clinical-trial-in-chinese-adolescents-with-obesity-302639274.html
- https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/boehringer-advances-obesity-treatment-mid-stage-development
- https://www.biospace.com/press-releases/lir-life-sciences-files-provisional-patent-application-for-needle-free-delivery-of-glp-gip-based-obesity-therapies
- https://www.prnewswire.com/news-releases/nitinotes-announces-first-patient-treated-in-pivotal-ease-clinical-trial-evaluating-the-endozip-automated-suturing-system-for-esg-302638021.html
- https://markets.businessinsider.com/news/stocks/zealand-pharma-outlines-metabolic-frontier-2030-strategy-to-become-a-generational-biotech-leader-in-obesity-and-metabolic-health-1035635616
- https://www.pfizer.com/news/press-release/press-release-detail/pfizer-enters-exclusive-collaboration-and-license-agreement
- https://www.thepharmaletter.com/biontech-news/prolynx-bags-70-million-to-advance-obesity-candidates-names-ceo
- https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916468
- https://www.spherixglobalinsights.com/amid-escalating-market-investment-physicians-forecast-rapid-uptake-of-oral-semaglutide-upon-approval-in-obesity-according-to-spherix-global-insights/
- https://www.morningstar.com/news/business-wire/20251210840902/crux-adds-obesity-management-medicine-to-its-newly-launched-employer-benefit-platform